- Abstract Number: PP11
We Suffered For Decades, But Then She Was Born
- Abstract Number: 1979
Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis
- Abstract Number: 0168
What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment
- Abstract Number: 1854
What Is Our Regional Delay to Diagnosis in Patients with Axial Spondyloarthropathy – Are We Hitting the Target? Data from a Multi-centre UK Patient Cohort
- Abstract Number: 1279
What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference
- Abstract Number: 1680
What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?
- Abstract Number: 0213
When Should I Get My Next Booster? Active Surveillance of COVID-19 Breakthrough Infections in Canadian Patients with Immune-Mediated Inflammatory Diseases
- Abstract Number: 2201
When Usual Care Is Not so Usual: Facing the Challenges of Protocol Violations and Generalisability When Running a Strategy Trial. the Example of the Cluster-Randomized TICOSPA Trial
- Abstract Number: 1385
Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers
- Abstract Number: 0517
Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?
- Abstract Number: 1901
Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration
- Abstract Number: 1884
Which Cell Pattern in Immunological Bronchoalveolar Lavage (BAL) Is Associated with a High-resolution Computer Tomography (HRCT) Pattern at the Onset of Inflammatory Rheumatic Disease with Interstitial Lung Disease?
- Abstract Number: 2198
Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
- Abstract Number: 0788
Whole Exome Sequencing and Evolutionary Action Missense Mutation Analysis Identifies MICB as a New SSc Susceptibility Locus and the Interferon Pathway as Contributors to SSc Pathogenesis
- Abstract Number: 0996
Will Patients Engage with Digital Technologies as Part of Routine Healthcare?
- Abstract Number: 2173
Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients
- Abstract Number: 1304
Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy
- Abstract Number: L16
Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial
- Abstract Number: 2432
Wnt Signaling Drives Pathogenic Stromal Inflammation in Inflammatory Arthritis
- Abstract Number: 0521
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
- Abstract Number: 1973
Work-related Impact in Young Patients with Chronic Back Pain Awaiting a Magnetic Resonance Imaging
- Abstract Number: 1190
Worsening of Pain as Perceived by Patients Is Not Reflected by an Annual Standardized Questionnaire
ACR Convergence 2023
November 10-15, 2023. San Diego, CA.